文献速递痛风与晶体性关节病

减重与目标血清尿酸水平:年度体检的纵向研究

Weight Reduction and Target Serum Urate Level: A Longitudinal Study of Annual Medical Examination.
PubMed 文献 · Arthritis Rheumatol · 2024-10-31

该纵向研究分析2012年10月至2022年10月年度体检者数据,评估减重与血清尿酸变化及高尿酸血症者达到血清尿酸<6 mg/dL的关联。结果显示小幅减重仅带来小幅血清尿酸变化,部分高尿酸血症者可通过中至大幅减重达到目标血清尿酸水平。

要点

  • 小幅减重(1.0-4.9 kg)仅带来小幅血清尿酸变化,均值变化为-0.10 mg/dL。
  • 中幅减重(5.0-9.9 kg)和大副减重(≥10 kg)的血清尿酸均值变化分别为-0.34 mg/dL和-0.64 mg/dL。
  • 高尿酸血症者中,中至大幅减重与达到血清尿酸<6 mg/dL的调整相对风险升高相关。

核心结论

  • 小幅减重仅与小幅血清尿酸变化相关;部分高尿酸血症者可通过中至大幅减重达到目标血清尿酸水平。

研究设计与样本

  • 纵向研究,分析2012年10月至2022年10月年度体检参与者系统收集的数据。
  • 共纳入58,630名合格参与者,中位年龄46岁,女性占51.3%,超重占19.4%,中位血清尿酸水平5.3 mg/dL,5.6%有痛风和/或高尿酸血症史,中位随访5.3年内共336,814次就诊。
  • 暴露为两次连续就诊间的体重变化,分为极小(≤0.9 kg,参照组)、小幅(1.0-4.9 kg)、中幅(5.0-9.9 kg)和大幅(≥10 kg)。

主要发现

  • 与极小体重变化相比,调整相关协变量后,小幅减重(1.0-4.9 kg)的血清尿酸均值变化为-0.10 mg/dL(95%CI -0.10至-0.09 mg/dL)。
  • 与极小体重变化相比,中幅减重(5.0-9.9 kg)的血清尿酸均值变化为-0.34 mg/dL(95%CI -0.36至-0.32 mg/dL)。
  • 与极小体重变化相比,大幅减重(≥10 kg)的血清尿酸均值变化为-0.64 mg/dL(95%CI -0.70至-0.58 mg/dL)。
  • 高尿酸血症参与者中,小幅减重达到血清尿酸<6 mg/dL的调整相对风险为1.25(95%CI 1.15-1.37),中幅减重为2.82(95%CI 2.43-3.27),大幅减重为5.27(95%CI 4.15-6.70)。
  • 对应需治疗人数:小幅减重61.1,中幅减重8.5,大幅减重3.6。

关键数值与推荐

  • 高尿酸血症定义为前次就诊时血清尿酸水平≥7 mg/dL。
  • 结局包括两次连续就诊间血清尿酸变化,以及高尿酸血症参与者达到血清尿酸<6 mg/dL。
  • 体重变化分组:极小≤0.9 kg(参照),小幅1.0-4.9 kg,中幅5.0-9.9 kg,大幅≥10 kg。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Our objective was to evaluate associations of weight reduction with serum urate (SU) changes and achieving an SU level <6 mg/dL in the real-world setting, outside of specific weight reduction interventions. METHODS: We analyzed systematically collected data of annual medical examination participants from October 2012 to October 2022. Exposure was weight change (increase or decrease) between two consecutive visits, categorized as minimal (≤0.9 kg, reference), small (1.0-4.9 kg), moderate (5.0-9.9 kg), and large (≥10 kg). Outcomes included SU changes between two consecutive visits and achieving an SU level <6 mg/dL in participants with hyperuricemia (SU level ≥7 mg/dL at the previous visit). RESULTS: We identified 58,630 eligible participants (median age 46 years, 51.3% female, 19.4% with overweight, median SU level 5.3 mg/dL, and 5.6% with a history of gout and/or hyperuricemia) with 336,814 visits over a median of 5.3 years. After adjustment for relevant covariates, linear general estimating equations estimated mean SU changes based on observed weight reductions (vs minimal changes) were as follows: small, -0.10 mg/dL (95% confidence interval [CI] -0.10 to -0.09 mg/dL); moderate, -0.34 mg/dL (95% CI -0.36 to -0.32 mg/dL); and large, -0.64 (95% CI -0.70 to -0.58 mg/dL). In participants with hyperuricemia, adjusted relative risks for achieving an SU level <6 mg/dL by modified Poisson regression were 1.25 (95% CI 1.15-1.37) in small weight reductions, 2.82 (95% CI 2.43-3.27) in moderate weight reductions, and 5.27 (95% CI 4.15-6.70) in large weight reductions, with corresponding numbers needed to treat of 61.1 for small weight reductions, 8.5 for moderate weight reductions, and 3.6 for large weight reductions. CONCLUSION: Small weight reductions were associated with only small SU changes. Some participants with hyperuricemia can achieve the target SU level with moderate to large weight reductions.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Fukui S, Okada M, Shinozaki T, et al. Weight Reduction and Target Serum Urate Level: A Longitudinal Study of Annual Medical Examination. Arthritis Rheumatol. 2024. PMID: 39400956. doi:10.1002/art.43027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。